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ABSTRACT 
 For the past 40 years, most patients with Primary Hyperparathyroidism (PHPT) 
have presented with the asymptomatic form of PHPT. Despite the dominance of the 
asymptomatic PHPT phenotype, current National Institutes of Health (NIH) indications 
for parathyroidectomy fail to identify as many as 80% of patients afflicted with 
asymptomatic PHPT. To date, studies of the therapeutic benefits of parathyroidectomy 
among asymptomatic PHPT patients have relied on general health questionnaires and 
patient reports of their satisfaction with the surgery. The purpose of the present study was 
to implement objective, quantifiable metrics in assessing whether or not asymptomatic 
PHPT patients experience improvements in domains salient to them such as mobility and 
cognitive function following parathyroidectomy. This information may help set the 
foundation for more accurately identifying patients who would benefit from 
parathyroidectomy. We hypothesized that asymptomatic patients would exhibit 
improvement in motor-cognitive outcomes following successful parathyroidectomy.    
 We performed a single-center prospective assessment of gait, frailty, and motor-
cognitive function among patients diagnosed with PHPT. Demographics, medical history, 
  v 
and perioperative labs were recorded. Pre- and post-surgical measures included the Fried 
frailty criteria, the PROMIS 10 Global Health Scale, and gait analysis under habitual 
(ST), walking while performing working memory test (dual-task: DT), and fast-walking 
conditions, an upper extremity frailty (UEF) test, and an interactive trail-making task 
(iTMT) . Descriptive statistics, Chi-squared, 2-sample t tests, and repeated measures 
analysis of variance were applied where appropriate. 
 22 parathyroidectomy patients (male 7; 31.8%); median age of 54.9 (standard 
deviation=15.5) years participated. The prevalence of frailty/pre-frailty was 60% at 
baseline and reduced to 33% at 3 weeks post-op. PROMIS 10 physical health improved 
significantly by 3 months post-op (d=0.93, p=0.010). DT and fast walk velocities were 
significantly increased by 3 weeks post-op (p<0.050) with highest effect size observed 
during DT conditions (24%, Cohen's effect size d=1.30 , p=0.017). ST velocity increased 
but not significantly (17.5%, d=0.46, p=0.422). Results from UEF tests and iTMT did not 
achieve statistical significance at any visit date. 
 Asymptomatic PHPT patients experience significant resolution of motor-
cognitive symptoms as measured by DT gait and PROMIS 10 Global Health Scale 
following parathyroidectomy performed by a skilled surgeon. 
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 INTRODUCTION 
Prognostication Among Patients with Primary Hyperparathyroidism 
Primary hyperparathyroidism (PHPT) is the autonomous excess production of 
parathyroid hormone (PTH) by the parathyroid glands [1]. Approximately 100,000 
individuals in the United States are diagnosed with PHPT annually and many others are 
diagnosed with hyperparathyroidism secondary to hypocalcemia [2]. Symptomatic PHPT 
classically presents as painful bones, renal stones, abdominal groans, and psychic moans 
[5]. Parathyroidectomy is the definitive treatment for symptomatic PHPT and carries a 
high success rate of 95% as defined by location and incident-free removal of 
adenomatous parathyroid glands [1]. Although surgery is the most common and effective 
way to treat symptomatic PHPT in regards to achieving more favorable biomarkers, the 
degree to which parathyroidectomy improves a patient’s functionality and quality of life 
remains unknown [4]. Additionally current NIH guidelines for surgical intervention fail 
to identify as many as 80% of PHPT patients who present asymptomatically. Patients 
who present asymptomatically may either have a favorable prognosis sans surgical 
intervention or may experience dramatically improved quality of life following 
parathyroidectomy [1] [4]. 
Because function of the bone, muscles, and nervous system are compromised by 
the hypercalcemia and metabolic defects associated with PHPT, quantifying the degree of 
motor-cognitive impairment in asymptomatic PHPT patients using wearable sensors can 
potentially serve as an objective measurement of the functional benefits of 
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parathyroidectomy and differentiate good candidates for parathyroidectomy from those 
who would receive little to no benefit from parathyroidectomy. 
Treatment Guidelines for Asymptomatic PHPT are lacking  
 In the early 1990’s, the NIH Consensus Development Conference Panel crafted 
guidelines for identifying candidates for parathyroidectomy who are living with 
asymptomatic PHPT. Because PTH raises blood calcium, presence of 
musculoskeletal/neuromuscular symptoms such as nephrolithiasis and osteitis fibrosa 
cystica as well as metabolic biomarkers were included as parathyroidectomy criteria. 
However, these criteria fail to identify 75-80% of patients living with PHPT. Most 
patients with asymptomatic hyperparathyroidism present with indicators of poor health-
related quality of life (HRQOL) such as weakness, fatigue, mood swings, general 
malaise, and intellectual weariness [3][8]. To address the dearth of focus on HRQOL 
metrics as indicators for parathyroidectomy, in 2002, the NIH updated recommendations 
to include consideration of these subjective traits as indications for surgery [3]. However, 
these guidelines are difficult to widely implement due to a lack of reliable tools to assess 
parameters such as weakness and fatigue. Physicians often rely on intuition, past 
experience, and will of the patient when deciding whether or not parathyroidectomy is 
indicated among asymptomatic PHPT patients. 
Anatomy and Physiology of Parathyroid Glands 
 The four parathyroid glands in normal adult humans are embedded in the superior 
and inferior caudal aspect of the thyroid gland and exhibit bilateral symmetry. They are 
oval-shaped and are each approximately 3-8mm long in any direction and weigh 35-
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40mg individually [9]. Cells of the parathyroid glands consist of both oxyphil cells and 
chief cells. While the function of the oxyphil cells has not yet been elucidated, it is well-
established that parathyroid chief cells are the only cells in the body capable of producing 
the 85 amino acid peptide hormone, PTH [10][11]. Unlike most endocrine hormones, 
release of PHT does not rely on any central nervous system axis but is instead regulated 
by serum calcium levels. Serum calcium interfaces with the PTH production system via a 
cell-surface G-coupled protein calcium sensing receptor (CaSR) [12]. Serum calcium is 
negatively coupled to PTH release such that elevated calcium concentration detected by 
the CaR will halt production and release of PTH while low calcium concentration will 
stimulate production and release of PTH [10]. 
Function and Clearance of PTH 
 Target tissues of PTH include predominantly the bones, the renal tubules, and the 
intestines. However, PTH can also act on nonclassical tissues such as nervous, smooth 
muscle, and cardiac tissues [13]. PTH interacts with osteoblasts via a G-coupled protein 
PTH receptor (PTH1R) [14][15]. Osteoblasts then signal osteoclasts to initiate bone 
resorption. Thus, PTH stimulates osteoclastogenesis through an osteoblast intermediary 
[14]. PTH also acts on cells of the cortical thick ascending tubules to increase calcium 
reabsorption and stimulates hydroxylation of 25-hydroxy-vitamin D in the proximal 
convoluted tubule which increases calcium reabsorption in the intestine [10][16][17][19]. 
PTH has a half-life of approximately 4 minutes in the blood and is degraded in the 
kupffer cells of the liver. The peptide fragments resulting from degradation are then 
excreted in the urine [18]. 
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Pathophysiology of PHPT 
 Analyses of the cause of PHPT are currently speculative and inconclusive. It is 
suggested that 86.7% of PHPT cases are due to one or more solitary adenomatous 
parathyroid glands [10]. These adenomatous glands tend to exhibit a reduction in CaSR 
mRNA [19]. However, it is unclear whether reductions in CaSR mRNA are the primary 
cause of PHPT or whether these reductions are a response to elevated serum calcium 
levels [20]. 3.3% of PHPT cases are due to parathyroid carcinoma [10]. Alternative 
explanations assert there is a genetic component to PHPT. Approximately 10% of PHPT 
are causally linked to multiple endocrine neoplasia (MEN), a syndrome associated with 
the multiple endocrine neoplasia type 1 (MEN1) and multiple endocrine neoplasia type 2 
(MEN2) genes. 25-30% of patients with sporadic PHPT have mutations in MEN1 genes 
although they do not have MEN per se [20].  
The effects of excess circulating PTH are profound and wide-ranging. The most 
significant effects of elevated PTH are a disturbance in calcium homeostasis and loss of 
bone integrity [20][21][22]. Hypercalcemia leads to constipation and anorexia which are 
among the first symptoms experienced among those with PHPT [10]. Later complications 
of hypercalcemia include peptic ulcers, nephrolithiasis, pancreatitis, and dehydration 
[20].  Patients with asymptomatic PHPT also report psychiatric and neurocognitive 
disturbances although the causal mechanism of these ailments remains unclear [22][24-
26]. Psychiatric disturbances associated with PHPT include depression, anxiety, apathy, 
fearfulness, and lassitude [22]. The neurocognitive disturbances include impairments in 
memory, visuospatial reasoning, attention, and verbal fluency [22][27-31]. 
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Diagnosis of Primary Hyperparathyroidism 
Diagnosis of PHPT involves evaluation of family history and various biomarkers 
in the blood and urine. Detection of approximately 80% of PHPT cases occurs with an 
incidental observation of hypercalcemia without obvious signs or symptoms of PHPT 
[32]. If no drug can be identified as the cause of hypercalcemia, the patient must present 
with hypercalcemia on two separate measurements, have normal renal function, and have 
a PTH concentration of greater than 3.0 pmol/L for definitive diagnosis of PHPT. 
Indications for Surgical Intervention in Treatment of PHPT 
Parathyroidectomy is the definitive treatment for PHPT and is successful in 95% 
of cases [32]. However, as many as 80% of patients with PHPT do not meet criteria for 
parathyroidectomy and there is no objective evidence for these criteria [1][4][32]. Criteria 
for parathyroidectomy as recommended by the NIH include serum calcium adjusted for 
albumin greater than 0.25 mmol/L above the upper limit of the laboratory reference 
range, urine calcium greater than 10 mmol per day, creatinine clearance reduction by 
30% or more, age less than 50 years, and/or likelihood of patient follow-up is faint. Any 
one of these criteria can be met for indication of surgery [32]. 
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SPECIFIC AIMS 
There is currently no clinical technique to quantitatively measure improvements in 
HRQOL or assess symptoms such as weakness, fatigue, and malaise. Valuation of these 
subjective traits has traditionally relied on questionnaires and informal patient self-
reporting [3][7]. Objective quantification of gait, motor-cognitive function, and frailty 
status may be the key to gauge the efficacy of parathyroidectomy in quality of life 
domains that are salient to the patient [3]. The content of this thesis details a pilot study 
aimed at assessing the potential for wearable sensors to measure therapeutic benefits in 
domains that are salient to patients such as mobility and cognition. 
The advent of wearable gyroscopes and accelerometers has made ExerGaming programs 
and gait and frailty analysis objective, cost-effective, and practically applicable in a 
clinical setting. Implementing methods to identify those who may not require 
parathyroidectomy can potentially spare patients and their family members the financial 
and emotional stresses associated with surgical procedures and contribute to more 
efficiently rationing limited surgical resources. Furthermore, measuring the benefits of 
parathyroidectomy in an objective manner may contribute to building a cache of 
information both patients and clinicians can use to perform a robust cost-benefit analysis 
when considering surgery for asymptomatic PHPT patients.   
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METHODS 
 
Design-wise, this study was a prospective cohort study with the aim of assessing 
functional outcomes among patients with PHPT following parathyroidectomy. This study 
took place over the course of of 6 months from September of 2016 to February of 2017 at 
Baylor St. Luke’s Medical Center; an urban clinical setting. The study was approved by 
the Baylor College of Medicine Institutional Review Board. 
 
Patient Eligibility and Recruitment  
Patients were recruited from a Baylor St. Luke’s endocrine surgery clinic and a 
day surgery unit at the Baylor St. Luke’s Episcopal Hospital. Both sites were under the 
supervision of a single physician collaborator enlisted by our team. Inclusion criteria for 
participation in the study was defined as age of 18 years or older and ability to ambulate 
for 100 meters without a walking aid. Those patients who had bilateral above the knee 
and/or above the elbow amputation or clinical diagnosis of dementia were excluded from 
the study. One of the 23 patients invited to participate in the study declined enrollment. 
The remaining 22 patients agreed to participate in the study following a thorough 
explanation of risks involved with participation in the study and documentation of 
informed consent. After consent to participate was obtained, demographic, motor-
cognitive function, gait, UEF, frailty, and general health questionnaire information was 
gathered. 
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Collection of Demographic Information 
 Demographic information was collected both immediately following the patient 
consenting procedure and retrospectively from the patient’s electronic medical record. 
All relevant demographic information was catalogued in a Health Insurance Portability 
and Accountability Act (HIPAA)-compliant server on our office computers. 
Assessment of Motor-Cognitive Function   
 A computer-based iTMT platform derived from the conventional paper-and-
pencil trail-making task was used as a tool to measure motor cognitive function within 
the current patient cohort. A combination triaxial gyroscope and accelerometer sensor 
(BioSensics LLC, Brookline, MA) was applied around both of the patient's ankle joints 
with Velcro bands. The human-computer interface was developed in Matlab ® 2013b and 
Psychophysics Toolbox Version 2.54. The iTMT test was set up in a quiet, private room. 
For the entirety of the assessment, the subject stood in front of the computer screen with 
the sensors applied wearing footwear of their choice. The screen was adjusted to the 
subject’s eye level and a trained test administrator was present for the duration of the test 
for the patient’s safety. The patients were given verbal instructions for completion of the 
test once before initiation of the test and were given the opportunity to answer questions. 
After confirmation that the patient did not have any further questions regarding the test, 
the assessment was started and no further instructions or encouragement was given by the 
test administrator.   
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The patient executed the test by partially transferring weight in the 
forward/backward/sideward/diagonal directions without losing contact of the plantar 
surface of the shoe with the ground. The corresponding ankle joint rotation was translated 
to a linear cursor movement on the computer screen in real-time. Essentially, the patient 
navigated the computer cursor by rotating her ankle joint. The patient navigated the 
cursor from a start circle to five targets arranged in a semicircle above the start circle with 
a random number or letter in each target. The subject was expected to navigate the cursor 
to targets in alternating alphanumeric order such that after moving to the target labeled 
“1”, the patient went to the target labeled “A” and then to target “2” and then to “B” and 
lastly to “3” (Figure 1). The subject had to navigate the trail quickly and accurately. Both 
correct execution and incorrect execution were met with feedback in the form of visual 
and auditory responses.  If navigation into the exact center of the targets takes between 
0.5 and 2 seconds, the border of the target circle turned red and the target circle exploded 
with a rewarding sound. If the patient took longer than 2 seconds to navigate to the 
correct target, the target turned green. If the subject made a mistake in reaching the right 
order, he/she received a visual and audio error signal. If the subject made 3 consecutive 
mistakes, the correct target blinked as a visual cue to guide him/her to reach the right 
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target. The test was concluded after the subject completed one cycle of the trail.
  
Figure 1. iTMT Administration Procedure and Computer Interface. The patient stands with sensors applied to 
ankle while a trained test administrator is present to supervise. The patient navigates to targets on the computer screen 
containing numbers and letters by rotating their ankles and pelvis [83]  
Assessment of Gait 
 Gait performance was assessed using 2 body worn combination triaxial gyroscope 
and accelerometer sensors (LegSys™, Biosensics LLC, USA) attached to each of the 
ankle joints using Velcro straps. Gait was assessed over a distance of 15 feet in an 
unobstructed, well-lit clinic hallway under 3 conditions: (1) walking at habitual speed 
(ST), (2) walking at a habitual speed under dual-task conditions; in this case walking 
while counting backwards (DT), (3) walking at their maximum speed (fast). The patients 
wore footwear of their choosing and did not use any form of walking aid. Based on the 
subject’s height and using a two-link inverse pendulum model the following spatio-
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temporal gait parameters were estimated: velocity normalized to height (m/sec), cadence 
(steps/min), stride time (sec), and swing phase as a percentage of the gait cycle. 
 
Figure 2. Pictorial Representation of UEF Test. Triaxial accelerometer-gyroscopes are applied around the patient’s 
wrist and forearm. The patient is instructed to perform 20 seconds of elbow flexion [69,70]. 
 
UEF Test 
 Each participant performed a 20-second trial of forearm flexion while wearing 2 
combination triaxial gyroscope and accelerometer sensors (sample frequency = 100Hz, 
BioSensics LLC, Brookline, MA) attached to the dominant upper-arm at the middle of 
the triceps and one on the wrist joint of the dominant arm using Velcro bands. The test 
was performed as the patient was in a seated position. Before the actual test, participants 
performed a short practice trial on their non-dominant arm. The patients were instructed 
to keep their upper arm immobilized at their side and only flex their forearm as fast as 
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they could for 20 seconds with full rise to near-shoulder level and full lowering to thigh-
level (Figure 2). They were verbally encouraged to perform forearm flexion as possible 
only once prior to the start of the test. No further encouragement was provided for the 
remaining duration of the test. Several outcome measures representing kinematics of the 
forearm flexion were derived using angular velocity and anthropometric information. 
UEF outcome measures included: 1) speed; 2) flexion rate; 3) power; and 4) moment. 
Measures of slowness included speed and flexion rate. Acceleration and weakness were 
assessed using power and moment. 
Frailty Assessment 
 The Fried frailty criteria was used as a validated assessment of frailty status. This 
criteria identifies patient weight loss, weakness (as measured by grip strength), slow 
walking speed, self-reported exhaustion, and low physical activity (PA) as components of 
the frailty syndrome [33]. Weight loss, exhaustion, and low PA were patient-reported, 
grip strength was measured using a dynamometer, and walking speed was assessment 
was done in conjunction with sensor-based gait analysis. A more detailed definition of 
each of these components can be found in table z. Testing positive for none of these five 
components indicates non-frailty, testing positive for one or two components indicates 
pre-frailty, and testing positive for three or more components indicates frailty.   
PROMIS Global 10 Short Form Questionnaire 
 The PROMIS Global 10 Short Form questionnaire was implemented as a metric 
of general mental and physical health. It is an NIH-validated 10 point Likert scale 
questionnaire and was administered following sensor-based and frailty assessments. This 
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instrument is standardized to the general US population. Scores range from 4 to 20 with a 
higher score representing more of the concept being measured. Thus, a mental health 
score of 20 indicates a better quality of mental health than a mental health score of 4. 
Items included on the PROMIS 10 Global Short Form can be found in Table 1. 
 
Table 1. Parameters of the PROMIS 10 Global Short Form. The PROMIS 10 Global Short Form is a general health 
questionnaire that assesses both physical and mental dimensions of health status. Questions presented in this table are 
answered on a Likert scale.  
 
Physical Health Dimensions 
 
 
Mental Health 
Dimensions 
 
Physical and 
Mental Health 
Dimensions 
In general, how would you 
rate your physical 
health? 
In general, would you say 
your quality of 
life is:. 
In general, would 
you say your health 
is… 
To what extent are you able 
to carry out your 
everyday physical activities 
such as walking, 
climbing stairs, carrying 
groceries, or moving a 
chair? 
In general, how would you 
rate your mental 
health, including your 
mood and your ability to 
think? 
In general, please 
rate how well you 
carry out 
your usual social 
activities and roles. 
How would you rate your 
pain on average? 
In general, how would you 
rate your satisfaction 
with your social activities 
and relationships? 
How would you rate your 
fatigue on average? 
How often have you been 
bothered by emotional 
problems such as feeling 
anxious, depressed or 
irritable? 
 
Statistical Analysis 
 The data was analyzed using IBM SPSS Statistics 24® Software. Analysis of 
demographic information including age and anthropometric measurements was 
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conducted using descriptive statistics. Frequency of frailty was calculated using a Chi-
squared test. Gait velocity according to frailty was calculated with implementation of 
one-way analysis of variance. Paired samples t-tests were used to quantify changes in 
sensor-based tests and the PROMIS 10 Global Short Form from baseline to various post-
op assessments. Significance was considered at an alpha level below 0.05. 
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RESULTS 
 
 Of the 22 patients included in this study, 68.2% were female and the average age 
of the patients was 54.9 years. Their average body mass index (BMI) was 29.2 kg/m2. 
Other demographic information can be found in Table 2. 77.2% of patients received their 
baseline assessment the day of surgery while the baseline measurements for the 
remaining patients were obtained an average of 16.8 days prior to surgery with a 
maximum of 18 days before surgery and a minimum of 3 days before surgery. 3 week 
follow ups occurred an average of 26.4 days after the day of surgery and 3 month follow 
ups occurred an average of 97.7 days after the day of surgery. 3 patients were lost at 3 
weeks follow-up. As of the date this work was submitted, 4 patients have been assessed 
at 3 months follow-up group. 
 
Table 2. Demographic Information of Present Study Population. Averages and standard deviation are given for 
anthropometric parameters. Frequency and raw number are provided for gender and sample size. 
Demographic   Mean (SD) 
N 22 
Gender (% male) 31.8 
Age (years) 54.95 (15.51) 
Height (cm) 166.18 (10.97) 
Weight (kg) 78.99 (16.97) 
BMI (kg/m2) 29.27 (6.57) 
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Fried Frailty Status Changes 
 At baseline measurement, Fried frailty status was assessed among 20 of the 22 
patients. 8 were non-frail, 11 were pre-frail, and 1 was frail (Table 3). Exhaustion was the 
most frequently reported component of the frailty syndrome with 75% of pre-frail/frail 
patients reporting exhaustion. 5 pre-frail/frail patients demonstrated weakness, 4 reported 
low PA, 2 were designated as slow-walkers, and 1 had unintentional weight loss of more 
than 10 pounds in the past year (Figure 3). 
 
Table 3. Influence of Demographic Parameters on Frailty Statutus. Averages and standard deviation are given for 
anthropometric parameters. Frequency and raw number are provided for gender and sample size. Demographic factors 
such as gender, age, and BMI do not have a significant influence on frailty status. 
Demographic (SD) Non-Frail (N=8) Frail/Pre-Frail 
(N=12) 
P-Value 
Gender (% Male) 50 25 0.274 
Mean Age, years 54.75 (14.59) 55 (19.07) 0.974 
Mean Height, cm 168.9 (9.41) 165.95 (11.17) 0.546 
Mean Weight, kg 82.99 (23.48) 76.70 (12.39) 0.443 
Mean BMI, kg/m2 28.91 (7.45) 29.08 (6.39) 0.957 
 
 At 3 weeks follow-up, 12 of 17 patients were non-frail, 5 were pre-frail, and none 
were frail. The frail patient in the baseline group transitioned from frail to pre-frail by 3 
weeks follow-up. Exhaustion and low PA were the most commonly reported components 
of the frailty syndrome in the 3 weeks follow-up group and 1 pre-frail individual in this 
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group exhibited weakness. Chi square analysis indicated there was no statistically 
significance between the frequency of pre-frailty/frailty at baseline and the frequency of 
pre-frailty/frailty at 3 weeks follow-up (p=0.197).  
 
 
Figure 3. Breakdown of Pre-Op Frailty Status by Component. At baseline, the main contributor to pre-frail/frail 
status was exhaustion followed by weakness, low PA, slowness, and lastly, weight loss. 
 
 By 3 months follow up, 1 of the 4 patients assessed thus far tested positive for 
frailty (Table 4). This patient was unable to walk due to a recent injury, did not engage in 
any PA, and reported exhaustion. 1 patient was pre-frail in this group due to weakness 
(Figure 4). This patient also had a clinical diagnosis of muscular dystrophy from an early 
age. The remaining 2 patients were non-frail. Again, there was no significant difference 
between the frequency of frailty at baseline as compared to the frequency of frailty at 3 
months follow-up according to chi square analysis (p=0.221) (Table 5).     
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Table 4. Frailty Status Changes from Pre-Op to 3 Months Post-Op. The frequency .of frailty reduced to 0 by 3 
weeks post-op but increased to 25% at 3 months post-op. Pre-frailty frequency exhibited a downward trend while non-
frail status exhibited a general upward trend. 
Status 
Pre-Op 
N=20 
3w Post-Op 
N=17 
3mo Post-Op 
N=4 
Frail 0.05 0 0.25 
Pre-Frail 0.55 0.294 0.25 
Non-Frail 0.4 0.706 0.5 
 
Table 5. Significance of Frailty Status Changes from Pre-Op to 3 Months Post-Op. Pairwise comparison was 
conducted for frailty frequency changes. Although the frequency of frailty reduced from the pre-op by 3 weeks post-op, 
the change was not significant. Furthermore, the frequency of frailty was split evenly between the frail/pre-frail group 
and the non-frail group by 3 months post-op as compared to the pre-op group. 
Measurement 
Period 
# Pairwise Samples Pearson Chi-
Square 
P-Value 
Pre-Op to 3 Weeks 
Post-Op 
16 1.67 0.197 
Pre-Op to 3 Months 
Post-Op 
4 1.50 0.221 
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Figure 4.Frailty Changes by Component. The frequency of all contributors to frailty with the exception of slowness 
decreased by 3 months post-op.  
 
Gait Changes 
At baseline, 11 of the 22 enrolled patients completed a walking assessment under 
the ST condition. Only 50% of the enrolled patients completed gait assessment because 
most patients were assessed the day of surgery and there was only a short period of time 
they were able to spend with the research team. These 11 patients demonstrated an 
average stride velocity of 0.50 m/sec (normalized to their height). At 3 weeks follow-up, 
15 of the 22 enrolled patients completed a walking assessment under the ST condition. 
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The average stride velocity among these patients was 0.60 m/sec (Table 6). A total of 8 
pairwise assessments from baseline to 3 weeks follow-up were completed for the ST 
condition (Table 7). Gait information from the 3 months follow-up visits has not been 
included the current analysis as 1 of the 4 patients was unable to walk the day of the 
assessment and another was using ankle-foot orthoses to walk. The remaining 2 patients 
seen at 3 months follow up did not participate in gait assessment at baseline. Among the 
8 patients for whom a pairwise 2-sample t-test was performed, the difference in ST stride 
velocity from baseline to 3 weeks follow-up was not significant (p=0.422). The cadence 
for these 8 individuals was on average not significantly changed at 3 weeks follow-up 
when compared to baseline (p=0.511). Stride time did not significantly change at 3 weeks 
follow-up (p=0.569).    
 The same 11 patients who completed gait assessment under the ST condition also 
completed gait assessment during the DT condition at baseline. The average stride 
velocity for these individuals was lower than during ST conditions at 0.42 m/sec. At the 3 
weeks follow-up visit, 14 patients completed the DT gait assessment and performed with 
an average stride velocity of 0.55 m/sec (Figure 5). 7 pairwise data sets for DT gait 
assessment were completed. Interesting, while walking velocity under the ST condition 
did not increase significantly from baseline to 3 weeks follow-up, stride velocity under 
the DT condition did increase for the 7 patients with pairwise data (p=0.017). Pairwise 
comparison also revealed that cadence was not significantly changed by 3 weeks follow-
up (p=0.074) nor did stride time change significantly (p=0.296). 
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 9 patients at baseline completed a fast walk gait assessment and 15 completed a 
fast walk gait assessment at 3 weeks follow-up. The average stride velocity was 0.68 
m/sec at baseline. For the 15 patients assessed at 3 weeks follow up, this value increased 
to 0.84 m/sec. The same 7 patients with DT pairwise data also completed fast walk 
assessment. The fast walk stride velocity increased significantly from baseline to 3 weeks 
follow-up (p=0.024). Neither the cadence nor the stride time was significantly changed 
by 3 weeks follow-up was significantly increased (p=0.328 and p=0.551). 
 
Table 6. Changes in Velocity from Pre-Op to 3 Weeks Post-Op. Average velocity changes from the pre-op 
measurement to the 3 weeks post-op measurement indicate that only DT walking velocity, which carries a cognitive 
component, changed significantly by 3 weeks post-op. While the mean ST and fast velocities increased, the magnitude 
of increase was not significant. 
 Pre-Op Velocity (height/sec) 3 Weeks Follow-Up 
Velocity (height/sec) 
Condition N Mean SD N Mean SD P-Value Effect Size 
ST 11 0.50 0.13 15 0.60 0.18 0.144 0.663 
DT 11 0.42 0.11 14 0.55 0.17 0.026 0.902 
Fast 9 0.68 0.14 15 0.84 0.20 0.180 0.871 
 
Table 7. Pairwise Comparison of Gait Parameters from Pre-Op to 3 Weeks Post-Op. Across gait parameters such 
as stride velocity, cadence, stride time, and swing, only velocity under DT and fast conditions was sensitive to changes 
from pre-op. 
   
Pre-Op 3w Post-Op 
  
Parameter Condition Pairwise N Mean SD Mean SD P-
Value 
Effect 
Size 
Velocity (height/s) ST 8 0.53 0.14 0.62 0.23 0.422 0.462 
DT 7 0.41 0.12 0.62 0.18 0.017 1.296 
Fast 7 0.71 0.14 1.58 0.26 0.024 1.419 
Cadence 
(steps/min) 
ST 8 100.53 14.29 102.69 13.74 0.511 0.153 
DT 7 90.48 21.25 97.79 19.57 0.074 0.033 
Fast 7 126.30 17.35 129.49 18.01 0.328 0.187 
Stride Time (s) ST 8 1.21 0.14 1.19 0.16 0.569 0.161 
DT 7 1.40 0.33 1.30 0.22 0.296 0.351 
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Fast 7 0.97 0.13 0.95 0.12 0.551 0.141 
Swing (% of gait 
cycle) 
ST 8 38.45 1.45 39.48 1.20 0.060 0.773 
DT 7 38.39 1.70 39.69 1.26 0.245 0.863 
Fast 7 42.57 1.656 42.32 1.63 0.736 0.153 
 
 
Figure 5. Stride Velocity Changes from Pre-Op to 3 Weeks Post-Op. Stride velocity was significantly increased 
under DT conditions but not under either ST or fast conditions.   
 
 At baseline, interesting observations were made when gait performance was 
assessed as a factor of frailty status. Those who were identified as frail or pre-frail at 
baseline demonstrated significantly reduced stride velocity under the DT condition when 
compared to those who were non-frail (p=0.024). However, ST and fast walk 
performance was not significantly different between the pre-frail/frail and non-frail 
groups. Furthermore, swing as a percentage of time of the gait cycle during the fast walk 
was significantly higher at baseline among the non-frail group than among the pre-
0
0.2
0.4
0.6
0.8
1
1.2
ST DT Fast
St
rid
e 
Ve
lo
ci
ty
 (h
ei
gh
t/s
ec
) 
 23 
frail/frail group (p=0.008) (Figure 6). Swing was not significantly different from baseline 
to 3 weeks post-op under pairwise comparison. 
 
 
Figure 6. Swing as a Percentage of the Gait Cycle by Frailty Status. Frail/pre-frail individuals exhibit a larger swing 
phase as a percentage of the gait cycle under fast walk conditions.   
 
iTMT Changes 
 iTMT was completed 13 of the 22 patients at baseline. The average time it took 
these patients to complete this exercise was 67.78 seconds and they made an average of 
2.21 errors as determined by navigating to the wrong target during one cycle of the 
exercise. At the 3 weeks follow up visit, 16 patients completed iTMT and the average 
time it took to complete the iTMT exercise decreased to 62.525 seconds with an average 
of 1.87 errors. Although the amount of time and number of errors during the iTMT 
exercise decreased by 3 weeks after surgery, neither of these changes was statistically 
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significant (Figure 7a, Figure 7b). Pairwise, 9 patients completed both baseline and 3 
weeks follow up iTMT exercises. Among these patients, there was no statistically 
significant difference in the amount of time to or number of errors implicated in the 
iTMT exercise from baseline to 3 weeks follow-up. 
 
a) b) 
Figure 7. Time and Number of Errors During iTMT Exercise. a) The amount of time spent completing the iTMT 
exercise decreased from pre-op to 3 weeks post-op; though not significantly. b) The number of errors made during the 
iTMT exercise decreased although not significantly by 3 weeks post-op. 
 
UEF Changes 
 Significant changes in UEF parameters were not achieved at either 3 weeks 
follow-up or for the 3 patients assessed thus far at 3 months follow-up. Measures of 
speed, flexion rate, power, and moment registered above p=0.082 at 3 weeks follow-up 
and above p=0.064 at 3 months follow-up (Table 8). At 3 weeks, the DT flexion rate 
increased from 90 flexions/min to 100 flexions/min (p=0.082) while ST power increased 
from 141499 deg2/sec3 to 226530 deg2/sec3 (p=0.064) by 3 months follow-up (Table 9). 
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Table 8. Pairwise Comparison of UEF Parameters from Pre-Op to 3 Weeks Post-Op. In a sample of 7 pairwise 
comparisons of changes in UEF performance, no parameter was significantly changed from pre-op to 3 weeks post-op. 
UEF Parameter (N=7) Pre-Op Mean (SD) 3 Weeks Post-Op Mean (SD) P-Value 
ST Speed 837.93 (629.00) 764.65 (494.19) 0.702 
DT Speed 696.149 (563.68) 670.30 (455.70) 0.856 
ST Flexion Rate 120.92 (40.33) 121.64 (32.58) 0.936 
DT Flexion Rate 90.04 (28.89) 100.07 (25.63) 0.082 
ST Power 145158.56 (153798.74) 169599.61 (205444.85) 0.087 
DT Power 134875.71 (164361.09) 113739.33 (136264.96) 0.380 
ST Moment 95395.96 (81167.92) 79386.44 (73365.54) 0.296 
DT Moment 67026.06 (57029.14) 60931.20 (52702.79) 0.591 
 
Table 9. Pairwise Comparison of UEF Parameters from Pre-Op to 3 Weeks Post-Op. In a sample of 3 pairwise 
comparisons of changes in UEF performance, no parameter was significantly changed from pre-op to 3 months post-op. 
UEF Parameter (N=3) Pre-Op Mean (SD) 3 Months Post-Op Mean 
(SD) 
P-Value 
ST Speed 760.16 (559.87) 1096.65 (201.86) 0.259 
DT Speed 787.74 (436.65) 1029.60 (99.29) 0.353 
ST Flexion Rate 99.44 (21.27) 104.58 (23.72) 0.507 
DT Flexion Rate 92.88 (19.86) 93.04 (20.47) 0.990 
ST Power 14199.92 (125575.00) 226530.34 (87153.86) 0.064 
DT Power 142374.47 (127223.36) 185023.21 (37853.73) 0.496 
ST Moment 69370.08 (44154.16) 100748.71 (32775.42) 0.193 
DT Moment 70224.13 (23742.34) 91481.55 (24006.58) 0.345 
 
PROMIS 10 Changes 
 Pairwise PROMIS 10 was available for 12 patients by 3 weeks post-op and for 3 
patients at 3 months post-op. Improvements in PROMIS 10 parameters were obtained 
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only at 3 months follow-up. No significant changes in PROMIS 10 responses were 
observed at 3 weeks follow-up (Table 10). At 3 months follow up, PROMIS 10 physical 
health improved significantly from a baseline mean score of 6.50 to a mean score of 7.83 
(p=0.010). The mental score actually deteriorated at the 3 week follow-up visit with a 
mean score of 10.42 at baseline and a mean score of 10.33 at 3 weeks follow-up (Table 
11). The mental health score later increased to 10.67 at 3 months follow-up from a 
baseline mean of 10.50 for the 3 patients for whom pairwise data was available 
(p=0.872). 
 
Table 10. Pairwise Comparison of UEF Parameters from Pre-Op to 3 Weeks Post-Op. In a sample of 3 pairwise 
comparisons of changes in UEF performance, no parameter was significantly changed from pre-op to 3 weeks post-op. 
PROMIS 10 Score Pre-Op Mean 
(SD) 
3 Weeks Post-Op Mean (SD) P-Value 
Physical Health 7.17 (1.59) 7.17 (1.40) 0.259 
Mental Health 10.42 (2.84) 10.33 (1.73) 0.141 
 
Table 11. Pairwise Comparison of UEF Parameters from Pre-Op to 3 Months Post-Op. In a sample of 3 pairwise 
comparisons of changes in UEF performance, no parameter was significantly changed from pre-op to 3 months post-op. 
PROMIS 10 Score Pre-Op Mean 
(SD) 
3 Months Post-Op Mean (SD) P-Value 
Physical Health 6.50 (1.38) 7.83 (1.47) 0.037 
Mental Health 10.50 (2.67) 10.67 (2.73) 0.204 
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DISCUSSION 
 
 While studies using general health questionnaires have been conducted to assess 
the therapeutic benefits of parathyroidectomy, to date, there has been no study of 
functional benefits provided to asymptomatic PHPT patients undergoing 
parathyroidectomy using objective, quantifiable metrics. The central goal of this study 
was to provide information regarding whether or not and for whom parathyroidectomy 
may improve motor functionality and cognition among those who do not present with the 
classical symptoms of PHPT using reliable, practical, and quantifiable assessment tools.  
Frailty Among Asymptomatic PHPT Patients 
 The Fried frailty criteria was used as a validated measure of frailty for the purpose 
of the present study because there have been few studies of frailty among asymptomatic 
PHPT patients despite the fact that both conditions share similar characteristics. Both 
frail individuals and those with PHPT tend to be older women and often exhibit motor-
cognitive deficits which can manifest as weakness, loss of appetite, lethargy, and feed 
into a vicious cycle with low PA [33,34,40]. These symptoms stem from a frail 
individual’s loss of physiologic reserve defined here as the sum total of an individual’s 
physical ability, vigor, and cognition [35]. Frailty is considered to be a geriatric syndrome 
and has not been studied specifically among PHPT patients who can be an average age of 
49.8 to 66.0 years depending on the gender composition of the population in question. 
 Currently, a significant number of studies demonstrate assessment of frailty in 
patients undergoing surgery predicts important health-related quality of life outcomes 
such as risk of postoperative complications, length of stay, discharge to an assisted living 
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facility, and risk of hospital readmission [67,68]. In the present study, 68.2% of 
participants were female and the average age was 54.9 years. At baseline, 60% of patients 
were identified as being frail or pre-frail. This rate is remarkably high as studies of older 
males and females aged 65-69 years in the United States exhibit a frailty/pre-frailty 
prevalence of 48.4% [41]. Considering that older age is a significant risk factor for 
frailty, it is interesting that although our study population was on average 10 years 
younger than a nationally representative group of older individuals, the prevalence of 
frailty/pre-frailty was almost 12% higher in our group [42]. Studies specifically focusing 
on older women at an average age of 76.9 report a frailty/pre-frailty prevalence of 63.3% 
which is closer to the 60% prevalence of frailty/pre-frailty in the present study [43]. Thus, 
it may be that having PHPT confers additional risk for frailty/pre-frailty beyond either 
older age or female gender alone.  Frailty has been demonstrated to be associated with a 
multitude of unfavorable outcomes and adverse events following surgery. Frail 
individuals tend to have reduced heart rate variability which places them at higher risk for 
sudden death, heart failure, and coronary artery disease [36,37]. Frailty is also associated 
with immune system suppression and impaired balance dynamics which hinders a 
patient’s ability to live autonomously [33,38,39]. Because frail individuals have reduced 
physiologic reserve, their ability to rebound and recover from a major stressor, such as 
surgery, is significantly diminished. However, the majority of patients in the present 
study, although frail/pre-frail, apparently benefited from parathyroidectomy. The 
reduction in components of the frailty phenotype observed among patients by 3 weeks 
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follow-up, while not significant, indicate that parathyroidectomy may contribute to 
alleviation of subjective symptoms such as exhaustion, weakness, and low activity.       
 Exhaustion and muscle weakness are the least robust indicators of frailty and past 
studies have demonstrated that upper extremity muscle weakness may be less sensitive to 
predict adverse events than lower extremity muscle weakness among older women [44, 
45]. Thus, it is possible that participants in the present study recovered well from surgery 
because they were not predominantly afflicted by weight loss which is the most robust 
indicator of frailty but were instead living with mild indicators of frailty. Furthermore, 
the skill level of the surgeon performing parathyroidectomy has been shown to influence 
the success and outcome of the surgery [46]. The surgeon performing parathyroidectomy 
for patients in the present study has been the chief of endocrine surgery at a high-volume 
urban hospital for over 7 years so it is possible that positive patient outcomes are partly 
due to surgical skill level. 
Gait Analysis May Indicate Cognitive Improvements 
 Traditionally, assessment of gait has required employment of a gait lab, a portable 
camera-based motion capture system, or a space-occupying pressure sensor mat; all of 
which can be costly and impractical in a clinical setting [50-56]. For this reason, only 
case studies have been conducted to assess gait among PHPT patients [46-48]. To the 
best of our knowledge, this is the first study conducted which uses gait analysis as a 
metric for motor-cognitive performance among a cohort of PHPT patients. 
 Gait velocity is well-established to have significant value in predicting health-
related outcomes such as risk of fall, overnight hospitalization, impaired ability to climb 
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10 steps or walk a quarter of a mile, and death [57, 58].  Particularly, slow gait velocity 
has been documented to be associated with cardiovascular death [59]. More importantly, 
DT walking is a more ecologically valid measure of motor-cognitive function than either 
ST or fast walking because multitasking during a walking bout, such as talking on the 
phone or determining whether or not it is safe to cross the street, is the rule rather than the 
exception in a typical day. Furthermore, a decline in cognition is associated with a 
patient’s loss of independence, reduced satisfaction with quality of life, increased risk of 
falling, increased burden on caregivers, and higher healthcare costs [88-90]. 
 In the present study, the average gait velocity during ST, DT, and fast walking 
conditions increased by 3 weeks post-parathyroidectomy. However, only the DT increase 
in gait velocity increased significantly. Engaging in a cognitive task such as counting 
backwards while walking (dual-tasking) is a method to isolate the cognitive control 
component of gait [60][61]. Considering that PHPT patients very commonly report 
motor-cognitive impairments, the information from this study suggests PHPT patients 
may experience improvements in motor-cognitive function following parathyroidectomy 
[62]. This improvement may benefit patients by improving their ability to learn as well as 
enhance their memory and verbal abilities [22]. 
 Other spatiotemporal parameters of gait improved by 3 weeks post-
parathyroidectomy however, none of the improvements were statistically significant. 
Cadence is linked to risk for all-cause mortality and cardiovascular specific mortality 
with a decrease in cadence increasing risk for both types of mortality [63]. Because 
velocity increased over time but cadence did not, it must be that PHPT patients 
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undergoing parathyroidectomy experience an increase in stride length; although, this 
assumption was not tested in the present study. 
 The time that passes between two successive contacts with the ground using the 
same foot is known as stride time and its increase has been shown to be influenced by 
disruptions in neural processes and balance control [64]. In the present study, stride time 
reduced slightly by 3 weeks post-op but did not to a degree to warrant statistical 
significance. Thus, while PHPT patients may experience slight resolution of neral and 
balance control disruptions, the improvement is modest and could be due to factors other 
than parathyroidectomy. Interestingly, stride time during DT conditions reduced with the 
highest effect size of all three walking conditions; although not significantly. Increased 
stride time variability is associated with a higher risk for falls under dual task conditions 
in older adults [65]. Testing stride time variability in addition to stride time may prove to 
be a fruitful endeavor in future studies. 
 Normally, swing phase as a percentage of time of the entire gait cycle registers at 
around 40% while the stance phase composes the remaining 60%. In the present study, 
patients consistently measured near the 40% norm for swing phase of the gait cycle. 
Reduced swing time is associated with lower extremity muscle weakness [66]. It is 
notable that when compared to non-frail PHPT patients, frail/pre-frail PHPT patients 
experienced a significant reduction in swing as a percentage of the gait cycle. This may 
indicate that exhibiting frailty/pre-frailty with diagnosis of PHPT increases susceptibility 
to muscle weakness. 
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iTMT Performance Among Asymptomatic PHPT Patients 
 There were no statistically significant changes in iTMT performance among the 
patients enrolled in this study following surgery. While the iTMT program, based on the 
paper trail-making task, has previously been used to distinguish healthy control subjects 
from patients with mild cognitive impairment from patients with Alzheimer ’s disease, it 
does not seem this tool is sensitive to changes in cognitive status among asymptomatic 
PHPT patients following surgery [83]. Alternatively, it may be that the type of cognitive 
impairment or “brain fog” experienced by these patients does not truly change 
significantly. It is unclear as to which hypothesis is more valid as questionnaires, patient 
reports, and tests of cognition have revealed conflicting results among PHPT patients 
undergoing parathyroidectomy. Asymptomatic PHPT patients commonly suffer from a 
decline in cognition; specifically memory [84]. Studies of PHPT patients have 
demonstrated improvements in reasoning, attention, and memory following 
parathyroidectomy [27, 30, 34, 85]. However, one of these same studies have shown that 
skills such as short-term visual memory and fine motor coordination do not change 
following parathyroidectomy [27]. The paper trail-making task is designed to test visual 
search and scanning as well as attention [86, 87].The computer-based iTMT used in the 
present study requires execution of visual search and scanning as well as lower-extremity 
motor function [83]. Thus, the lack of change in iTMT score observed is in-line with 
other studies that have shown no change in skills related to visual search, scanning, and 
motor coordination. A confirmation of the types of cognitive improvements experienced 
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by PHPT patients undergoing parathyroidectomy was not included in the design of the 
present study but does warrant further elucidation.  
UEF Results 
 The UEF test is an experimental tool that has previously been demonstrated to 
identify frailty in community-dwelling adults greater than 65 years in age. The UEF test 
has a sensitivity and specificity rating of 100% in identifying frailty and a sensitivity and 
specificity rating of 87% and 95% respectively in identifying pre-frailty in this older 
adult population [69]. This tool has also been demonstrated to identify frailty among 
older bed-bound trauma patients at an average age of 79±9 years with a sensitivity and 
specificity of 94% and 86% respectively [70]. In the present study, the 4 parameters 
chosen for analysis were not intended to predict frailty but were instead used to study 
changes in slowness, acceleration, and weakness following parathyroidectomy. Because 
speed, flexion rate, power, and moment were not significantly different from pre-op to 
any visit in the post-op period under either the ST or DT conditions, it may be that UEF 
parameters are not sensitive to detect changes in motor-cognitive status among 
parathyroidectomy patients. It is unlikely that significant motor-cognitive improvements 
do not occur after parathyroidectomy as gait analysis demonstrated increase in stride 
velocity following parathyroidectomy under both DT and fast conditions. 
 The theoretical basis for the UEF test originates from studies that have shown that 
alterations in gait speed result from changes in arm swing [71]. Thus, slowness could be 
derived from parameters such as UEF speed and flexion rate [69,70]. However, in the 
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context of this study, the evidence does not suggest that changes in gait velocity are 
reflected in changes in arm swing among PHPT patients undergoing parathyroidectomy. 
PROMIS 10 Demonstrates Improvements in Physical Health 
 The theoretical basis for the PROMIS 10 General Health short form is that 
various patients’ experiences of illness and disease share underlying traits and 
characteristics. General health questionnaires are an attempt to translate these personal 
experiences into a standardized code [75-78].  Measures of general health have been 
traditionally been useful in improving communication between clinicians and patients 
and identifying disabled individuals [73][74]. The physical health scale component of the 
PROMIS 10 General Health short form measures general physical health, pain level, 
physical function, and fatigue to indicate the level of overall physical health. The mental 
health scale component includes dimensions related to quality of life, satisfaction with 
personal social life, and emotional problems that are used to probe overall mental health 
[72]. The PROMIS 10 Global Health short form has specifically been implemented 
among patients with rheumatological defects for whom domains such as physical 
functioning, pain, social well-being, and fatigue are of key interest [78]. Because patients 
with asymptomatic PHPT commonly present with muscle weakness and fatigability, it 
was hypothesized that the PROMIS 10 questionnaire would elucidate the changes in 
health status of our patient population [79,80].  
 In the present study, at baseline among the 3 weeks post-op pairwise group, mean 
scores of physical and mental health were at the 27th and 40th percentile respectively as 
compared to the general U.S population. By 3 weeks follow-up in this group, physical 
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health remained at the 27th percentile and mental health reduced to the 39th percentile. 
For the pairwise data available at 3 months post-op, scores of physical and mental health 
were at the 25th and 40th percentile respectively. The physical health score increased 
significantly at 3 months post-op to the 29th percentile while the mental health score 
increased but not significantly to the 41st percentile at the time of this visit. 
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